Abstract: span style="font-size: 10.5pt; line-height: 16px; color: rgb(51, 51, 51);">DaTscan imaging successfully differentiated underlying dementia with Lewy bodies (DLB) from Alzheimer's disease (AD).
March 21, 2013 – In patients with mild cognitive impairment (MCI), DaTscan imaging successfully differentiated underlying dementia with Lewy bodies (DLB)
from Alzheimer's disease (AD).
In a recent study,1
researchers at Mayo Clinic (Rochester,
MN) used DaTscan imaging, SPECT imaging with a radioactive iodine-based tracer,
to compare the findings on DaTscan between
patients with MCI, AD and LBD. Reduced striatonigral uptake on DaTscan reflects
dopamine deficiency, a finding typical of DLB. They predicted that MCI patients
with negligible parkinsonism, but who have other features suggesting underlying
DLB, would have reduced striatonigral uptake compared to those with AD or
amnestic MCI (aMCI), but uptake in AD and MCI will be greater than in DLB.
The team of researchers
performed DaTscan imaging on 25 subjects (mean age 71 years, 23 male) 3-6 hours
after injection of 3-5 mCI of 123I Ioflupane (DaTscan). As predicted, they concluded
that the striatonigral uptake is lowest in DLB and highest in AD. Uptake in
those with naMCI and/or RBD is more similar to DLB while those with aMCI and/or
absence of RBD is more similar to AD. Further work in much larger numbers of
MCI subjects (with an adequate number of females) will determine the potential
utility of DaTscan in differentiating underlying LBD from AD in those with MCI.
Reference: Boeve B, Lowe V, Kantarci K, et
al. DaTscan findings in patients with mild cognitive impairment, Alzheimer’s
disease and dementia with Lewy bodies. Neurology. February 12, 2013;80(Meeting Abstracts 1): IN3-1.008.
For more information: www.mayoclinic.com